ABVC BioPharma, Inc.
ABVC
$2.41
-$0.12-4.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 9.62% | 56.34% | 77.84% | 49.38% | 62.88% |
| Total Depreciation and Amortization | -31.15% | -17.70% | 7.87% | 32.10% | 2,391.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -19.33% | -68.12% | -94.44% | -20.88% | -47.07% |
| Change in Net Operating Assets | -32.20% | 15.24% | -101.53% | -165.44% | -123.96% |
| Cash from Operations | -34.04% | 36.84% | 67.50% | 61.77% | 63.54% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -540.85% | -55.25% | -34.75% | -34.75% | 47.50% |
| Cash from Investing | -540.85% | -47.44% | -26.82% | -26.82% | 49.37% |
| Total Debt Issued | 33.05% | 104.91% | 163.22% | -16.77% | -52.84% |
| Total Debt Repaid | -68.52% | -146.38% | -106.65% | 69.99% | 63.44% |
| Issuance of Common Stock | 326.17% | 179.25% | 32.40% | -6.81% | -14.08% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -100.00% | -105.44% | -84.51% | -79.05% |
| Cash from Financing | 141.79% | -16.51% | -33.09% | -42.47% | -52.95% |
| Foreign Exchange rate Adjustments | 107.25% | 20.05% | -96.17% | -1,147.62% | -150.13% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 123.95% | 66,620.00% | 108.88% | 121.78% | 58.66% |